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Pancreatic cancer is notorious for its poor prognosis. The histopathologic characteristic 
of pancreatic ductal adenocarcinoma (PDAC), which is the most common type, is fibrosis 
within tumor tissue. Although fibrosis within tumor tissue is thought to impede drug 
therapy by interfering with the intratumoral accumulation of anti-tumor drugs, this 
hypothesis has yet to be proven directly in preclinical models. Here, we evaluated the 
effect of enhanced fibrosis on intratumoral accumulation of macromolecular drugs by 
increasing fibrosis in a murine tumor model of subcutaneously xenografted BxPC-3, a 
human PDAC cell line. When fibroblast growth factor-2 (FGF-2) was co-administered 
upon BxPC-3 inoculation, stromal fibrotic area was increased and was characterized by 
augmented murine collagen accumulation compared to inoculation of BxPC-3 alone. We 
discovered that the intratumoral accumulation of intravenously administrated fluorescein 
isothiocyanate-dextran of 2,000,000 Da (2 MDa) was significantly reduced in the FGF-2 
co-administered tumors despite unaltered hyaluronan accumulation and pericyte coverage 
of the tumor neovasculature and increased lymphangiogenesis. The model established 
and analyzed in this study, characterized by increased fibrotic component, provides a 
preclinical animal model suited to predict the intratumoral accumulation of 












Pancreatic cancer is well known for its dismal prognosis. The cancer is often 
inoperable at diagnosis due to its highly metastatic and invasive nature. Therefore, 
chemotherapy is an important treatment modality for pancreatic cancer [1] although its 
efficacy to date is far from being satisfactory. Pancreatic ductal adenocarcinoma (PDAC) 
in particular, the most common type of pancreatic cancer, has a 5-year relative survival 
rate of 6% and a median survival rate of 6 months [1,2]. Marked fibrosis, or desmoplasia, 
which is a histological feature of PDAC [2], is considered to be a factor explaining the 
refractoriness of PDAC to chemotherapy. Fibrotic tissue within the tumor consists of 
several types of extracellular matrix (ECM) components, such as collagen, hyaluronan, 
and fibronectin [3]. Previous reports have shown that a decrease in ECM components 
within tumor models in vivo or in vitro results in enhanced intratumoral accumulation of 
anti-tumor drugs, especially of macromolecules [4–8]. However, no reports to date have 
demonstrated that an increase of ECM components limits intratumoral accumulation of 
macromolecules in vivo.  
 Difficulty in evaluating the effects of enhanced fibrosis on the intratumoral 
accumulation of anti-tumor drugs is a consequence of the lack of animal models in which 
the amount of fibrosis can easily be regulated and increased. Although xenografts of 
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established human tumor cell lines into immunodeficient animals is widely used as animal 
models of human tumors, fibrosis within xenograft tumor tissue is often diminished 
compared to clinical specimens [9,10]. We previously reported that the BxPC-3 
subcutaneous xenograft model has some levels of fibrosis, greater in amount than that in 
most animal cancer models, but far less than that found in human pathologic specimens 
of the disease [11]. While some genetically engineered murine models of pancreatic 
cancer have marked fibrosis, researchers have to wait 6-9 months before the tumors grow 
large enough to analyze [2], and the degree of fibrosis cannot easily be modulated. 
Recently, we have shown that enhanced fibrosis may impair the intratumoral 
accumulation of drugs using a novel in vitro fibroblast three-dimensional culture model 
[12]. However, little is known about how to enhance fibrosis in vivo and its consequences.  
Extent of fibrosis is known to correlate positively with fibroblast growth factor-
2 (FGF-2) mRNA level in clinical pancreatic tumor specimens [13]. FGF-2 induces 
fibrosis by promoting the production of collagen and fibronectin in activated pancreatic 
stellate cells (PSCs) in humans, which are thought to be a major source of ECM in 
pancreatic cancer and chronic pancreatitis [14–16]. Moreover, FGF-2 neutralization has 
been shown to counteract the induction of fibronectin production in primary PSCs derived 
from clinical pancreatic cancer specimens by supernatants from pancreatic cancer cell 
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lines [17]. These findings suggest that FGF-2 may promote fibrosis in pancreatic cancer.  
In this study, we report a novel way to enhance fibrosis by using xenografted 
BxPC-3 cells co-administered with FGF-2 in nude mice, and investigate whether 
enhanced fibrosis affects intratumoral accumulation of macromolecular drugs. 
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Materials and Methods 
Cell and animal model 
The human pancreatic adenocarcinoma cell line BxPC-3 was obtained from the 
American Type Culture Collection (VA, USA) and cultured in RPMI 1640 medium (Life 
Technologies, CA, USA) with 10% fetal bovine serum (Hyclone, UT, USA) and 1% 
penicillin/streptomycin (Life Technologies). Male BALB/c-nu/nu mice, 4–6 weeks of age, 
were obtained from CLEA Japan (Tokyo, Japan), Sankyo Labo Service (Tokyo, Japan), 
and Charles River Laboratories, (Tokyo, Japan). All animal experimental protocols were 
performed in accordance with the policies of the Animal Ethics Committee of the 
University of Tokyo. 
BxPC-3 subcutaneous xenograft model was established with a total of 1 x 106 
cells suspended in 200 L of Matrigel (BD biosciences, CA, USA)/phosphate buffered 
saline (PBS) mixture (1:1) inoculated into the left flank of each mouse. To enhance 
fibrosis, 1 g/mL of FGF-2 (Peprotech, NJ, USA) and 100 g/ml of heparin (Novo 
Nordisk, Bagsvaerd, Denmark) were added in the cell suspension before inoculation. 






Formalin-fixed, paraffin-embedded tumor samples were cut at a thickness of 4 
m and subjected to hematoxylin-eosin (HE) and AZAN staining. BZ-9000 (Keyence, 
Osaka, Japan) was used to observe the samples and obtain photographs. For quantification 
of AZAN positive areas, tile-scanned images were merged using BZ analyzer (Keyence) 
and then the proportion of AZAN positive areas was calculated by dividing intratumoral 
AZAN positive area (in pixels) by the whole tumor area (in pixels), using Adobe 
Photoshop Elements (Adobe Systems Incorporated, CA, USA) and ImageJ (National 
Institute of Health, MD, USA). 
 
Immunohistochemistry 
Harvested tumor samples were also immediately embedded in Optimal Cutting 
Temperature (OCT) compound (Sakura Finetek Japan, Tokyo, Japan) and frozen at -80°C. 
The frozen samples were cut at a thickness of 10 m, briefly fixed with Mildform (Wako 
Pure Chemical Industries, Osaka, Japan), washed and air dried. The sections were then 
blocked with Blocking One (Nacalai Tesque, Kyoto, Japan) for 30 min at room 
temperature, and incubated with primary antibodies overnight at 4°C. The samples were 
then washed and incubated with the appropriate secondary antibodies for 1 hour at room 
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temperature. The secondary antibodies used in this study were anti-rat Alexa Fluor 488, 
anti-rat Alexa Fluor 594, anti-rabbit Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 (all 
purchased from Life Technologies). After washing briefly, nuclei were stained with 1 
g/mL of 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Life Technologies). 
The samples were observed using BZ-9000 or DMI6000 B AFC (Leica Microsystems, 
Wetzlar, Germany). The primary antibodies used in this study were that against platelet 
endothelial cell adhesion molecule-1 (PECAM-1; BD biosciences), α-smooth muscle 
actin (α-SMA; Sigma-Aldrich, MO, USA), and lymphatic vessel endothelial hyaluronan 
receptor-1 (LYVE-1; Abcam, Cambridge, UK). Intratumoral PECAM-1 positive areas 
and intratumoral PECAM-1/α-SMA double positive areas were quantified using Adobe 
Photoshop Elements and ImageJ by dividing intratumoral PECAM-1 positive areas (in 
pixels) by whole tumor areas (in pixels), or by dividing intratumoral double positive areas 
(in pixels) by PECAM-1 positive areas (in pixels), respectively, for tile-scanned images 
obtained and merged using BZ analyzer. For quantification of LYVE-1 positive lymphatic 
vessels, ten fields per sample were taken using DMI6000 B AFC and the average numbers 
of lymphatic vessels were counted. Frequency of lymphatic vessels with lumen was 
calculated by dividing the number of lymphatic vessels with conspicuous lumen by total 




Evaluation of intratumoral hyaluronan accumulation 
For hyaluronan staining, formalin-fixed, paraffin-embedded samples were cut at 
a thickness of 4 m, deparaffinized, washed, and blocked with Blocking One for 30 min 
at room temperature. After blocking, the samples were incubated with 2.5 g/mL of 
biotinylated hyaluronan binding protein (biotin-HABP) (Hokudo, Sapporo, Japan) 
overnight at 4°C. The samples were then washed and incubated with 5 g/mL of Alexa 
Fluor 488 streptavidin (Life Technologies) for 1 hour at room temperature. Nuclei were 
stained with 1 g/mL of DAPI. For hyaluronidase treatment, some samples were washed 
with PBS (pH 5.5) just after blocking and incubated with 400 U/mL of hyaluronidase 
from bovine testes (Sigma-Aldrich) in PBS (pH 5.5) at 37°C for 2 hours. For 
quantification of hyaluronan accumulation, tile-scanned images were obtained and 
merged using BZ analyzer, and the average signal intensity in the tumor area was 
calculated using Adobe Photoshop Elements and ImageJ. 
 
Evaluation of intratumoral accumulation of FITC-dextran 
 Analysis of intratumoral accumulation of fluorescein isothiocyanate (FITC)-
dextran (average molecular weight 2 MDa) (Sigma-Aldrich) was done as follows. FITC-
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dextran was dissolved in physiological saline (Otsuka Pharmaceutical, Tokyo, Japan) and 
its concentration was adjusted to 10 mg/mL. The solution was intravenously administered 
into tumor-bearing mice (200 L per mouse). Six hours after administration, the tumor 
samples were harvested and immediately embedded in OCT compound and frozen at -
80°C. These samples were cut at a thickness of 10 m and fixed with Mildform for 5 min. 
Nuclei were stained with 1 g/mL DAPI. BZ-9000 was used to observe the samples. For 
quantification of intratumoral accumulation of FITC-dextran, tile-scanned images were 
obtained and merged using BZ analyzer and then the average signal intensity in the tumor 
area was calculated using Adobe Photoshop Elements and ImageJ. 
 
Evaluation of hydroxyproline amount 
Amount of collagen was quantified by measuring hydroxyproline content. 
Hydrolysis of the samples was performed following a previous report [18] with minor 
modifications. Briefly, excised tumor samples were trimmed, weighed and homogenized 
in 20 volumes of 6 N hydrochloric acid (HCl) (w/v). Homogenized samples were 
transferred into polypropylene micro tubes with O-ring screw caps (Sarstedt, Numbrecht, 
Germany) and incubated overnight at 121°C. The residue was removed using Amicon 
Ultra-4 (10 k) (Millipore, MA, USA). 10 L of each sample was transferred into a 96-
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well plate (Thermo Fisher Scientific, MA, USA) and hydroxyproline content was 
measured using Hydroxyproline Assay Kit (Biovision, CA, USA), according to the 
manufacturer’s protocol. 
 
Total RNA extraction and quantitative real-time RT-PCR 
 Excised tumor samples were trimmed, cut into several small pieces and 
homogenized in Isogen (Nippon Gene, Tokyo, Japan) using Medimachine (Syntec 
International, Dublin, Ireland). Isolation of total RNA was performed according to the 
protocol for Isogen. Elimination of genome DNA in total RNA was performed using 
Nucleospin (Macherey-Nagel, Duren, Germany) according to the manufacturer’s 
protocol. First-strand cDNA synthesis was performed using 1 g of total RNA and 
PrimeScript Reverse Transcriptase (Takara Bio, Shiga, Japan). 
Quantitative real-time RT-PCR was performed using FastStart Universal SYBR 
green master (Roche, Basel, Switzerland) and Step One Plus (Life Technologies). Primers 
used in this experiment were: GAAGGTGAAGGTCGGAGTC and 
GAAGATGGTGATGGGATTTC for human GAPDH, AGCCAGCAGATCGAGAACAT 
and TCTTGTCCTTGGGGTTCTTG for human COL1A1, 
TGCAGTGGCAAAGTGGAGATT and TGCCGTTGAATTTGCCGT for murine Gapdh, 
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The data were expressed as means ± standard error (SE). Statistical evaluation 
of the data was carried out by two-tailed, unpaired Student’s t-test for comparison 
between two groups, using Microsoft Excel. Statistical significance was set at the level 






The FGF-2 co-administered BxPC-3 xenograft tumors harvested 3 weeks after 
inoculation showed markedly more fibrosis upon HE and AZAN staining compared to 
BxPC-3 xenografts without FGF-2 (Figure 1A). Indeed, the proportion of AZAN positive 
area was significantly increased with the co-administration of FGF-2 (Figure 1B). These 
findings indicate that FGF-2 enhanced fibrosis in the BxPC-3 subcutaneous xenograft 
model. 
 
Figure 1 FGF-2 increased tumor stroma in the BxPC-3 subcutaneous xenograft model. 
A: Representative photographs of HE and AZAN staining. FGF-2 markedly increased AZAN 
positive areas (AZAN staining, blue). scale bar: 50 m 
B: Quantification of the proportion of AZAN positive areas. FGF-2 significantly increased 
AZAN positive areas. error bars: mean ± SE, n =11 each, ***: p < 0.001 
 
We next investigated possible components of the ECM contributing to increased 
fibrosis: collagen, the major component of ECM, and hyaluronan, which is known to 
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impair intratumoral drug accumulation in genetically-engineered mouse models of 
pancreatic adenocarcinoma [4,5]. We first measured hydroxyproline content, a surrogate 
index of collagen content. FGF-2 co-administration significantly increased 
hydroxyproline content of the BxPC-3 xenograft model (Figure 2A). To assess the origin 
of collagen, the mRNA expression of murine Col1a1 (mCol1a1) and human COL1A1 
(hCOL1A1) was each quantified. The expression of murine collagen was significantly 
higher in the FGF-2 co-administered group (Figure 2B), while that of human was not 
significantly altered (Figure 2C), suggesting that the increased collagen content was not 
of BxPC-3 origin but rather host-derived.  
 
Figure 2 FGF-2 increased collagen 
in the BxPC-3 model. 
A: Hydroxyproline (Hyp) content of 
tumor tissue. The amount was 
significantly higher in FGF-2 co-
administered group. error bars: mean 
± SE, n = 6 each, ***: p < 0.001 
B: Expression level of murine Col1a1 
(mCol1a1). FGF-2 significantly 
increased mCol1a1 expression. Data 
were normalized to mGAPDH and expressed as relative value to the average of control group. 
AU: arbitrary unit, error bars: mean ± SE, n = 11 and 9, respectively, ***: p < 0.001 
C: Expression level of human COL1A1 (hCOL1A1). No significant difference was observed. 
Data were normalized to mGAPDH and expressed as relative value to the average of control 
group. AU: arbitrary unit, error bars: mean ± SE, n = 3 each. 
 
For hyaluronan, accumulation was observed both in tumor stromal and 
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parenchymal areas by fluorescent immunostaining (Figure 3A) which was confirmed by 
hyaluronidase treatment (Figure 3B), but no significant difference was observed 
regardless of FGF-2 co-administration (Figure 3C). Thus, the enhanced fibrosis induced 
by FGF-2 co-administration in this model seems, at least partly, to be due to enhanced 
collagen production by host-derived stromal cells but independent of hyaluronan 
accumulation.  
 
Figure 3 FGF-2 did not affect 
intratumoral accumulation of 
hyaluronan 
A: Hyaluronan binding protein (HABP, 
green) detected hyaluronan. Nuclei 
were stained with DAPI (blue). B: 
Hyaluronan staining using different 
sections of the same samples as A. 
Hyaluronan staining using different 
sections of the same samples as A. 
Treatment with hyaluronidase almost 
completely abrogated the fluorescence 
signal (green), thus confirming 
successful staining of hyaluronan. 
Nuclei were stained with DAPI (blue). 
scale bars: 50 m. C: Quantification 
of average fluorescence intensity of images as stained in A. Data were expressed as relative value 
to the average of control group. No difference was observed between the two groups. AU: 
arbitraty unit, error bars: mean ± SE, n = 5 each. 
 
Using this newly established murine pancreatic cancer model with enhanced 
fibrosis, we asked whether enhanced fibrosis could impair intratumoral accumulation of 
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macromolecular drugs by using FITC-dextran (average molecular weight 2 MDa) as a 
tracer mimicking the kinetics of macromolecular drugs. As in our previous report [19], 
six hours after intravenous administration of FITC-dextran solution, the tumors were 
harvested and intratumoral accumulation of FITC-dextran analyzed. Fluorescence signal 
from FITC-dextran was significantly lower in FGF-2 co-administered xenografts than 
those without FGF-2 (Figure 4A and B). Intratumoral accumulation of FITC-dextran was 
thus diminished in FGF-2 co-administered xenografts. 
 
Figure 4 FGF-2 reduced 
intratumoral accumulation of 
FITC-dextran (average molecular 
weight 2 MDa) 
A: Representative photographs of 
intratumoral accumulation of FITC-
dextran (molecular weight 2 MDa). 
The FITC signal (green) was reduced 
in the FGF-2 co-administered group. 
Nuclei were stained with DAPI 
(blue). scale bar: 50 m 
B: Quantification of average fluorescence intensity of FITC-dextran. The signal was 
significantly lower in FGF-2 co-administered group. Data were expressed as relative value to 
the average of control group. error bars: mean ± SE, n = 5 each, **: p < 0.01 
 
The accumulation of the macromolecules within the tumor is, however, not only 
influenced by fibrosis. We have previously reported that pericyte coverage of tumor 
vasculature impairs intratumoral accumulation of doxorubicin-encapsulated micelles in a 
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BxPC-3 subcutaneous xenograft model [11]. Therefore, we investigated whether FGF-2 
could influence vascular density and pericyte coverage of tumor vasculature, but no 
significant differences were observed in PECAM1 and -SMA immunostaining (Figure 
5A). Consistently, neither vascular density nor pericyte coverage was significantly 
different between the two groups (Figure 5B and C).  
 
Figure 5 FGF-2 did not affect vascular density and pericyte coverage 
A: Representative photographs of PECAM-1 and -SMA staining. No clear differences were 
observed. Blue indicates nuclei (DAPI). Scale bar: 50 m 
B: Quantification of the rates of PECAM-1 positive areas and PECAM-1/-SMA double 




FGF-2 is also known to promote lymphangiogenesis [20,21]. Relative scarcity 
of lymphatic vessels is thought to be a factor influencing intratumoral accumulation of 
macromolecules according to the enhanced permeability and retention (EPR) effect, in 
addition to leaky tumor vasculature [22,23]. Therefore, we stained tumor samples for 
LYVE-1, a well-known marker of lymphatic endothelial cells (Figure 6A). FGF-2 
significantly increased the density of lymphatic vessels within the tumor (Figure 6B). 
This was somewhat in contradiction to our expectations, since FGF-2 co-administration 
showed less, not more, accumulation of FITC-dextran. However, the frequency of 
lymphatic vessels with conspicuous lumen was significantly lower in the FGF-2 co-
administered group (Figure 6C), which may explain this discordance.  These findings 
overall indicate that changes in lymphangiogenesis do not necessarily contribute to the 
decrease in intratumoral accumulation of FITC-dextran in the FGF-2 co-administered 





Figure 6 FGF-2 promoted 
lymphangiogenesis in a BxPC-3 
xenograft model. 
A: Representative photographs of 
LYVE-1 staining. More lymphatic 
vessels were observed in the FGF-2 
co-administered group, but less 
lymphatic vessels with conspicuous 
lumen were observed in the FGF-2 
co-administered group. scale bar: 50 
m 
B: Quantification of intratumoral 
lymphatic vessel density. FGF-2 
significantly increased lymphatic 
vessel density. error bars: mean ± SE, 
n = 5 each, *: p < 0.05 
C: Quantification of the frequency of 
lymphatic vessels with conspicuous 
lumen. FGF-2 significantly 





In this study, we have shown that co-administration of FGF-2 augmented fibrosis 
in the BxPC-3 subcutaneous xenograft model. Further characterization of this model with 
enhanced fibrosis revealed that FGF-2 co-administration significantly increased 
intratumoral collagen deposition (Figure 2), while it did not clearly affect intratumoral 
hyaluronan accumulation (Figure 3), intratumoral vascular density or pericyte coverage 
of tumor vasculature (Figure 5). These results suggest that FGF-2 impaired intratumoral 
accumulation of FITC-dextran mainly by increasing intratumoral collagen deposition in 
our BxPC-3 subcutaneous xenograft model.  
Recently, nab-paclitaxel, a macromolecular formulation of paclitaxel bound to 
albumin, has been successful in clinical treatment of pancreatic cancer [24–26]. Although 
the formulation is a macromolecule of 130 nm in diameter before administration, the drug 
may soon decay to around a size of a single albumin molecule in the bloodstream [27–
29]. It is therefore not clear whether the results of this study using dextran of 2 MDa may 
immediately be applicable to predict the behavior of nab-paclitaxel in fibrotic tumor 
tissue. Furthermore, the pharmacokinetics of albumin-bound molecules, including nab-
paclitaxel, is not just a function of particle size but also of interactions with proteins in 
vivo such as secreted protein acidic and rich in cysteine (SPARC) [30]. The latter factor 
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is an interesting topic which warrants further studies. 
As the mechanism of increased fibrosis by FGF-2, previous reports have shown 
that FGF-2 promoted infiltration of immune cells in Matrigel plug assays [31,32]. Another 
group has shown that subcutaneous injection of FGF-2 augmented fibrosis via up-
regulation of monocyte/macrophage chemoattractant protein-1 (MCP-1) and increased 
infiltration of immune cells, such as macrophages, in newborn C57BL/6 mice [33]. Also, 
macrophages are known to induce fibrosis in several organs, such as heart and kidney. 
Our results suggest that collagen was derived from host stromal cells (Figure 2), but the 
precise mechanisms underlying FGF-2 enhanced fibrosis in our model remain to be 
elucidated. 
We have shown in this study using our new model that accumulation of 
macromolecule was less in the fibrosis-increased condition. However, factors which may 
explain the decrease in macromolecular accumulation other than the increase in the 
amount of fibrosis per se can be envisaged. First, interstitial fluid pressure (IFP) is a factor 
known to regulate intratumoral accumulation of anti-tumor drugs and is reported to be 
often increased in solid tumors [34–36]. Previous reports have shown that systemic 
administration of collagenase to tumor-bearing mice decreased intratumoral IFP and 
improved intratumoral accumulation of monoclonal antibodies and cationic liposomes 
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[6,7]. Therefore, enhanced fibrosis may act indirectly via an increase in intratumoral IFP 
in vivo. On the other hand, collagen may also be a physical barrier against intratumoral 
accumulation of macromolecular drugs because an in vitro study, in which IFP is not 
involved, has shown that treatment of spheroids of tumor cells with collagenase improved 
penetration of polyethylene nanospheres into the spheroids [8]. These suggest that 
increased IFP, in concert with the physical barrier posed by collagen bundles, may impede 
diffusion of macromolecular anti-tumor drugs into stromal areas. 
It is unclear from the present study whether changes in lymphangiogenesis, 
another potential factor as posited by the theory of the EPR effect [22,23], induced by 
FGF-2 co-administration influenced accumulation of macromolecules. Though previous 
studies have shown that interstitial fluid exits tissue through normal lymphatic vessels 
[20], it has not yet been clearly shown whether change in intratumoral lymphatic vessel 
can directly affect the intratumoral accumulation of macromolecules. That FGF-2 co-
administration promoted lymphangiogenesis in the BxPC-3 xenograft model at least in 
terms of LYVE-1 positive vessel density (Figure 6) was consistent with previous reports 
in vivo [21,37]. However, FGF-2 decreased the frequency of lymphatic vessels with 
conspicuous lumen, which may indicate an increase in collapsed lymphatic vessels within 
the tumor. Previous studies have indicated that intratumoral lymphatic vessels were non-
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functional [38]. These findings therefore suggest that increase of lymphangiogenesis in 
FGF-2-treated condition did not contribute to the intratumoral accumulation of FITC-
dextran. Further experiments such as ferritin microlymphangiography [39] may be 
necessary to evaluate the function of lymphatic vessels in this model. 
In summary, we have established a novel murine pancreatic cancer model with 
enhanced fibrosis by co-administering FGF-2 in the BxPC-3 subcutaneous xenograft 
model. The model we have established provides a preclinical model to predict 
intratumoral accumulation of macromolecules and to evaluate efficacy of drugs targeting 
the tumor stroma, especially in tumors with extensive fibrosis. 
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